WaveMan
WaveMan · Company
APVO · Aptevo Therapeutics Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

APVO Aptevo Therapeutics (APVO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001671584
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
2
13F, latest reported quarter
Conversions, 180 days
11
Codes C/M, not in net · no price filed

Aptevo Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Aptevo Therapeutics Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Grant Grady III
Director
BUY
2025-11-12 SECtraded 2025-11-10
13,513
$20.1K
-95.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 13,514 shares held after it.
  • No other insider bought within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Grant Grady III bought about $20.1K of APVO on Nov 10, 2025, the largest insider purchase at the company on our record; 2 funds added in the latest 13F quarter.
TANG CAPITAL PARTNERS LP
SELL
2021-11-26 SECtraded 2021-11-23
160,000
$1.5M
-100.0%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Nov 22, 2021.
  • No other insider sold within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider TANG CAPITAL PARTNERS LP sold about $1.5M of APVO on Nov 23, 2021, the largest insider sale at the company on our record; 2 funds added in the latest 13F quarter.
TANG CAPITAL PARTNERS LP
SELL
2021-11-26 SECtraded 2021-11-23
200,000
$2.0M
-100.0%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Nov 22, 2021.
  • The trade is 125.0% of the 160,000 shares held after it.
  • No other insider sold within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider TANG CAPITAL PARTNERS LP sold about $2.0M of APVO on Nov 23, 2021, the largest insider sale at the company on our record; 2 funds added in the latest 13F quarter.
TANG CAPITAL PARTNERS LP
SELL
2021-11-26 SECtraded 2021-11-23
50,889
$530.8K
-100.0%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Nov 22, 2021.
  • The trade is 14.1% of the 360,000 shares held after it.
  • No other insider sold within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider TANG CAPITAL PARTNERS LP sold about $530.8K of APVO on Nov 23, 2021; 2 funds added in the latest 13F quarter.
TANG CAPITAL PARTNERS LP
SELL
2021-11-26 SECtraded 2021-11-23
149,111
$1.7M
-100.0%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Nov 22, 2021.
  • The trade is 36.3% of the 410,889 shares held after it.
  • No other insider sold within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider TANG CAPITAL PARTNERS LP sold about $1.7M of APVO on Nov 23, 2021, the largest insider sale at the company on our record; 2 funds added in the latest 13F quarter.
19 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 14 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
2 funds bought in last quarter
the lowest in Pharma & Biotech
Revenue
-74.7% year over year
below 86% of Pharma & Biotech
Margin
-833.9% net margin
below 83% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
5.7% of the float short (float per yahoo 2026-10-27) · 1.9 days to cover · settled 2026-10-15
more than 54% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch APVO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-95.4%12M
-95%-63%-30%+2%2025-102025-122026-022026-042026-062026-082026-10 2025-11-10 · Grant Grady III bought $20.1K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns APVO: institutional holders (13F)

13F holdings, latest reported quarter
VANGUARD CAPITAL MANAGEMENT LLC
12,713 sh
$56.4K
GEODE CAPITAL MANAGEMENT, LLC
10,821 sh
$48.0K
VANGUARD FIDUCIARY TRUST CO
4,142 sh
$18.4K
UBS Group AG
730 sh
$3.2K
OSAIC HOLDINGS, INC.
360 sh
$1.6K

Congress trades in APVO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

APVO planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

APVO mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$43.7K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$56.4K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$7.6K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
1 active
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.3M
$1.3M
$952.6K
n/a
n/a
2024
$846.3K
$837.5K
$690.8K
n/a
n/a
2023
$916.4K
$810.0K
$663.4K
n/a
n/a
2022
$1.2M
$786.5K
$859.8K
-94%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 2 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

APVO financials

Revenue growth
-74.7%
XBRL, annual
Net margin
-833.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.1M
four quarters, 2022-01-01 to 2022-12-31
Net margin, TTM
-848.0%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.00x
LongTermDebt as filed 2023-12-31 (30 months older than the period end) (includes the current portion); equity 2026-06-30
Cash flow to debt
n/a
no debt to cover
Return on equity
-420.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-175.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-268.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Enterprise value
-$7.5M
market value at close 2026-10-27 on 2026-08-14 shares, plus LongTermDebt as filed 2023-12-31 (30 months older than the period end) (includes the current portion), minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenuen/an/an/a$3.1M
Operating income-$26.3M-$24.6M-$28.9M-$28.6M
Net income-$26.0M-$24.1M-$17.4M$8.0M
EPS (diluted)-87.27-31,460.23-2,316.831.57
Operating cash flow-$25.6M-$23.8M-$11.7M-$21.0M
Cash$21.6M$8.7M$16.9M$22.6M
Long-term debtn/an/a$0$1.5M
SEC XBRL, fiscal years, as known on 2026-10-28

APVO Stock Sonar score 5/7 axes

Find similar shapesCompare

APVO ranks highest on financial health (99th percentile) and risk and compliance (68th), and lowest on institutional and government (1st), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
10
Inputs
  • Return on equity-420.3% · 9 pct, sector of 545
  • Return on assets-175.2% · 13 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-268.0% · 7 pct, sector of 576
Financial health
100
Inputs
  • Debt to equity0.00x · 100 pct, sector of 352
  • Cash flow to debtno debt to cover
Growth
14
Inputs
  • Revenue growth, YoY-74.7% · 14 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
0
Inputs
  • Funds adding, latest quarter2 · 0 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
68
Inputs
  • Short interest, % of float+5.7% · 55 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+5.1% · 82 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies